Buy Tricor

Tricor

Tricor (Fenofibrate): Cholesterol-Lowering Pill Overview

Therapeutic class: Lipid-modifying agents (cholesterol management) Active ingredient: Fenofibrate Formulation: Oral pill (tablet) Available strengths: 160 mg, 200 mg

Tricor is a brand-name medication that contains fenofibrate as its active component. In Hong Kong, it is prescription-only and is regulated by the Pharmacy and Poisons Board under the local drug safety framework.

How Fenofibrate Works in the Body

Fenofibrate belongs to the fibrate class of lipid-modifying agents. It activates peroxisome proliferator-activated receptor-α (PPAR-α), a nuclear receptor that regulates genes involved in lipid metabolism. Activation of PPAR-α leads to:

• Increased lipoprotein lipase activity - enhances the breakdown of triglyceride-rich particles.
• Reduced hepatic production of very-low-density lipoprotein (VLDL) - lowers circulating triglycerides.
• Elevated synthesis of high-density lipoprotein (HDL) - modestly raises “good” cholesterol.

These actions collectively lower fasting triglyceride levels, modestly lower low-density lipoprotein (LDL) cholesterol, and raise HDL cholesterol. The therapeutic effect typically begins within 1-2 weeks, with the full lipid-modifying response observed after 4-8 weeks of consistent dosing.

Conditions Treated with Tricor

In Hong Kong, Tricor (fenofibrate) is approved for the following indications:

• Hypertriglyceridemia - elevated fasting triglyceride levels (≥ 200 mg/dL).
• Mixed dyslipidemia - combined high triglycerides and low HDL cholesterol, often seen in metabolic syndrome or type 2 diabetes.
• Primary hypercholesterolemia (adjunct) - used when statin therapy alone does not achieve target lipid levels, particularly when triglycerides remain elevated.

Patients are typically adults with documented lipid abnormalities who have not achieved optimal values with diet and lifestyle changes alone.

Evidence-Based Off-Label Uses

Some clinical studies and practice guidelines have explored fenofibrate beyond its approved indications. The following off-label applications have supporting evidence, but they are not approved by the Hong Kong regulatory authorities and should be considered only under specialist supervision:

• Primary Biliary Cholangitis (PBC): Small trials have shown fenofibrate can improve biochemical markers of cholestasis when added to ursodeoxycholic acid.
• Diabetic Retinopathy Prevention: Observational data suggest fenofibrate may reduce progression of retinopathy in patients with type 2 diabetes, independent of its lipid effects.

Disclaimer: Off-label use requires medical supervision and individualized risk assessment.

Who Should Use Tricor? Contraindications and Cautions

Absolute Contraindications

• Known hypersensitivity to fenofibrate or any excipients in the tablet.
• Severe hepatic impairment (e.g., Child-Pugh class C).
• Active gallbladder disease (gallstones, biliary obstruction).
• Pregnancy (fenofibrate is classified as category X - teratogenic risk).
• Breast-feeding (risk to the infant).

Relative Contraindications / Precautions

• Mild to moderate liver disease - requires baseline liver function testing and periodic monitoring.
• Renal impairment - dose adjustment may be needed; avoid use in end-stage renal disease unless benefits outweigh risks.
• History of myopathy or rhabdomyolysis, especially when combined with statins.

Special Populations

• Elderly: May have reduced renal clearance; start at the lower 160 mg dose and monitor.
• Patients with diabetes: Monitor fasting glucose, as fenofibrate can modestly affect glycemic control.

Safety Profile: Side Effects and Interactions

Common Side Effects

• Gastrointestinal discomfort (abdominal pain, nausea) - usually transient.
• Headache or dizziness.
• Elevated liver enzymes - periodic testing recommended.

Serious Adverse Events

• Myopathy / rhabdomyolysis: Rare but serious, especially when combined with statins.
• Severe hepatic injury: Indicated by jaundice, marked ALT/AST elevation.
• Renal function decline: Particularly in patients with pre-existing kidney disease.

Drug Interactions

• Statins (e.g., simvastatin, atorvastatin): Increased risk of myopathy; consider using lower-dose statins or alternative lipid agents.
• Warfarin: Fenofibrate may enhance anticoagulant effect; monitor INR more frequently when therapy is initiated or changed.
• Cyclosporine: May increase fenofibrate plasma levels, raising the risk of toxicity.
• Gemfibrozil: Combined fibrates markedly raise myopathy risk; avoid co-administration.

Food and Lifestyle Interactions

• Take with meals: Improves absorption and reduces gastrointestinal upset.
• Alcohol: Excessive intake can exacerbate triglyceride elevation and liver stress; limit consumption.
• Driving: No significant impairment, but dizziness may affect ability to operate machinery; use caution if symptoms occur.

If specific interaction data for Tricor are limited, patients should inform their healthcare provider of all concurrent medications, supplements, and herbal products.

Dosing and Administration Guidelines

• Standard adult dose: 160 mg tablet taken once daily with the main meal.
• Alternative strength: 200 mg tablet may be prescribed when a higher dose is clinically justified, typically in patients with very high triglyceride levels.
• Renal impairment: For creatinine clearance < 30 mL/min, reduce to 160 mg every other day or consider an alternative lipid-modifying agent.
• Hepatic impairment: Use the lowest effective dose and monitor liver enzymes every 3 months.

Administration Tips

• Swallow the tablet whole; do not crush or chew.
• Store tablets in a dry place at room temperature, away from direct sunlight.
• If a dose is missed, take it as soon as remembered unless the next scheduled dose is within 12 hours - then skip the missed dose. Do not double-dose.

Overdose Management

• Symptoms: Nausea, vomiting, abdominal pain, possible hepatic enzyme elevation.
• Action: Seek immediate medical attention; supportive care is the mainstay. No specific antidote is available.

Discontinuation

• No tapering is required for fenofibrate. Discontinue under physician guidance and consider re-checking lipid profile 4-6 weeks after stopping.

Monitoring and Follow-Up

• Baseline tests: Liver function (ALT, AST, bilirubin), renal function (serum creatinine, eGFR), fasting lipid panel, creatine kinase (CK) if muscle symptoms are present.
• Follow-up schedule:
• Lipid panel at 4-8 weeks after initiation, then every 3-6 months.
• Liver and renal function tests every 3 months for the first year, then annually if stable.
• Clinical assessment: Report persistent muscle pain, dark urine, jaundice, or unexplained fatigue promptly.

Storage and Handling

• Keep tablets in the original container, tightly closed, at room temperature (15-30 °C).
• Protect from moisture and direct sunlight.
• Discard any tablets that are discolored, chipped, or past the expiration date.
• For safe disposal, return unused medication to a pharmacy or follow local hazardous waste guidelines.

Medication-Specific Glossary

PPAR-α (Peroxisome proliferator-activated receptor-α)

A nuclear receptor that, when activated, increases the breakdown of triglycerides and raises HDL cholesterol.

Triglycerides

The main form of fat stored in the bloodstream; high levels are a risk factor for pancreatitis and cardiovascular disease.

Dyslipidemia

An abnormal amount of lipids (cholesterol, triglycerides) in the blood, often requiring pharmacologic treatment.

Myopathy

A disease of the muscle tissue that can cause weakness, pain, or, in severe cases, rhabdomyolysis.

Medical Disclaimer

This article provides educational information about Tricor (fenofibrate) and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.